PDE7A and multiple sclerosis: The successful developmentof an optimized PDE7 PET ligand would provide valuable insights intodisease progression, treatment response, and patient stratificationin conditions such as Alzheimer’s disease, Parkinson’sdisease, multiple sclerosis, and chronic inflammation.